Abstract:Background: Immunotherapy plays an important role in the treatment of triple-negative breast cancer (TNBC). This study aimed to identify immune-related genes that are associated with the prognosis of patients with TNBC as possible targets of immunotherapy, alongside their related tumor-infiltrating lymphocytes (TILs). Methods: The clinical data and gene expression profiles of patients with breast cancer were extracted from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases and divided into training (n = 1,053) and verification (n = 508) groups. CIBERSORT was used to predict the differences in immune cell infiltration in patient subsets that were stratified according to risk. Gene Ontology (GO) enrichment analysis was used to identify pathways associated with immune-related genes in patient subsets that were stratified according to risk. The clinical data and insulin-like growth factor 2 receptor (IGF2R) expression profiles of patients with breast cancer were extracted from METABRIC. The expression of IGF2R and TILs were evaluated in a cohort containing 282 untreated patients with TNBC. The correlations of IGF2R expression, TILs, and clinicopathological parameters with patient prognosis were analyzed in the whole cohort. Results: The prognostic model, which was composed of 26 immune-related gene pairs, significantly distinguished between high- and low-risk patients. Univariate and multivariate analyses indicated that the model was an independent prognostic factor for breast cancer. Among the identified genes, the expression of IGF2R significantly distinguished between high- and low-risk patients in TCGA ( P = 0.008) and in METABRIC patients ( P < 0.001). The expression of IGF2R was significantly associated with clinical risk factors such as TNBC, estrogen receptor (ER)–negative expression, human epidermal growth factor receptor 2 (HER2)–positive expression, and age ≤60 years old in METABRIC patients. In addition, the patients with IGF2R-positive expression had lower disease-free survival (DFS) rates than those with IGF2R-negative expression in the TNBC cohort (67.8% vs. 78.5%, P = 0.023). IGF2R expression also was significantly negatively correlated with TILs, particularly with CD8 + TILs and CD19 + TILs in the cohort of patients with TNBC. Conclusion: IGF2R can be used as an indicator of a poor prognosis in patients with TNBC and as a potential target and research direction for TNBC immunotherapy in the future.

Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis

An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment

Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets

A Novel Immune Checkpoint-Related Gene Signature for Predicting Overall Survival and Immune Status in Triple-Negative Breast Cancer

Combination of Immune-Related Network and Molecular Typing Analysis Defines a Three-Gene Signature for Predicting Prognosis of Triple-Negative Breast Cancer

Identification of an immune cell infiltration-related gene signature for prognosis prediction in triple-negative breast cancer

Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer

Immune Checkpoints Expression Patterns in Early-Stage Triple-Negative Breast Cancer Predict Prognosis and Remodel the Tumor Immune Microenvironment

Combination of Immune-Related Network and Subtype-Specific Analysis Define a Three- Gene Panel for Predicting Prognosis of Triple-Negative Breast Cancer

Identification of Immune-Related Risk Characteristics and Prognostic Value of Immunophenotyping in TNBC

Development of an immune-related prognostic biomarker for triple-negative breast cancer

Prognostic Implications of Immune-Related Genes’ (irgs) Signature Models in Cervical Cancer and Endometrial Cancer

Immune Microenvironment-Related Genes Contribute to Clinical Prognosis in Patients with Triple-Negative Breast Cancer

Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma

Identification of a Tumor Immune-Inflammation Signature Predicting Prognosis and Immune Status in Breast Cancer

Insulin-like Growth Factor-1 Receptor Gene Expression is Associated with Survival in Breast Cancer: a Comprehensive Analysis of Gene Copy Number, Mrna and Protein Expression

Pan-cancer analysis identified IGF2BP2 as a potential prognostic biomarker for multiple tumor types

Prognostic value of immune-related genes identified basing on immune infiltration in breast cancer

Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.

Immune-related Gene Signature Improves Prognosis Prediction in Patients with Breast Cancer and Associates It with Tumor Immunity and Inflammatory Response

Pan-cancer Analysis Reveals IGFL2 As a Potential Target for Cancer Prognosis and Immunotherapy.